Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex

Targeting the dysregulated BRaf-MEK-ERK pathway in cancer has increasingly emerged in clinical trial design. Despite clinical responses in specific cancers using inhibitors targeting BRaf and MEK, resistance develops often involving non-genomic adaptive bypass mechanisms. Inhibition of MEK1/2 by tra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Zawistowski, Jon S., Bevill, Samantha M., Goulet, Daniel R., Stuhlmiller, Timothy J., Beltran, Adriana S., Olivares-Quintero, Jose F., Singh, Darshan, Sciaky, Noah, Parker, Joel S., Rashid, Naim U., Chen, Xin, Duncan, James S., Whittle, Martin C., Angus, Steven P., Velarde, Sara Hanna, Golitz, Brian T., He, Xiaping, Santos, Charlene, Darr, David B., Gallagher, Kristalyn, Graves, Lee M., Perou, Charles M., Carey, Lisa A., Earp, H. Shelton, Johnson, Gary L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5340640/
https://ncbi.nlm.nih.gov/pubmed/28108460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0653
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados